Pfizer Pays Almost $120 Million For App That Detects COVID From a Cough

Pharma giant Pfizer has shelled out nearly $120 million to acquire a small Australian company claiming to have developed a smartphone app that can accurately diagnose COVID-19 by analyzing the sound of a cough. New Atlas reports: For around a decade small Australian digital healthcare company ResApp has been working on developing an algorithm that can diagnose respiratory illnesses by simply studying the sound of a patient's cough. Initially the system was trained to diagnose pneumonia, but by 2019 the researchers had shown the technology could effectively distinguish asthma, croup and bronchiolitis. When the pandemic struck in 2020 the team unsurprisingly quickly pivoted to incorporate COVID-19 diagnoses into its cough-recognition technology. By early 2022 the first data from a pilot trial testing the COVID algorithm revealed impressively good results.

The trial found the system could accurately detect 92% of positive COVID cases solely from the sound of a cough. The system also recorded 80% specificity, meaning only two out of every 10 people screened received false positive results. Soon after ResApp revealed these results pharma giant Pfizer began circling, initially offering around $65 million for the technology. Now, in a formal acquisition announcement, a deal has been finalized for Pfizer to buy ResApp for a massive $116 million.

Read more of this story at Slashdot.